Big Move For Avenue Therapeutics, Inc.
Tue, Mar 01, 2022 at 05:30 PM
Avenue Therapeutics, Inc. (ATXI:NASDAQ) soared at $0.61, representing a gain of 78.5%. The stock appeared on our News Catalysts scanner on Wed, Feb 16, 2022 at 01:35 PM in the 'BIOTECH' category. From Mon, Feb 14, 2022, the stock recorded 33.33% Up Days and 40.00% Green Days
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- Viscogliosi Brothers Acquisition Corp (VBOC:NASDAQ), 100%
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 78.46%
- CTI BioPharma Corp. (CTIC:NASDAQ), 63.16%
- GBS Inc. (GBS:NASDAQ), 50%
- Guardion Health Sciences, Inc. (GHSI:NASDAQ), 47.84%
- CooTek (Cayman) Inc. (CTK:NYSE), 36.24%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 36.11%
- Sky Harbour Group Corporation Class A (SKYH:NYSEMKT), 30.84%
- GWG Holdings, Inc. (GWGH:NASDAQ), 29.37%
- Avinger, Inc. (AVGR:NASDAQ), 28.31%